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ABSTRACT 
 
Background: Hybrid imaging using single photon emission computed tomography/low dose (x-ray) 
computed tomography (SPECT/LDCT) is of benefit in preoperative scintigraphy of primary 
hyperparathyroidism. The role of SPECT/LDCT in preoperative assessment of renal 
hyperparathyroidism has not yet been examined. The aim of the study was to determine whether 
SPECT/LDCT conferred any benefit over SPECT alone in terms of detection and/or localization of 
hyperfunctioning parathyroid tissue in this patient group. 
 
Methods: A retrospective study of patients with renal hyperparathyroidism and positive planar and 
SPECT scintigraphy was undertaken. All patients underwent planar scintigraphy using 
99m
Tc-
pertechnetate immediately followed by 
99m
Tc-sestamibi as well as SPECT/LDCT 60 min after 
sestamibi injection and a delayed static image to assess for differential washout at 2-3 hours. Planar 
subtraction images were generated. For each patient, two nuclear physicians reported on planar+ 
SPECT images followed by planar + SPECT/LDCT images (assisted by a radiologist). Confidence for 
the presence of hyperfunctioning parathyroid tissue as well as confidence of location was scored on a 
Likert-type scale. Interpretation of planar + SPECT was compared with interpretation of planar + 
SPECT/LDCT. The impact of LDCT on equivocal lesions and number of ectopic lesions detected was 
also assessed. 
 
Results:  Twenty patients (M:13; F:7) imaged between February 2008 and June 2011 were included 
[mean age: 40 years (24 – 55)]. Mean creatinine was 687 μmol/l (169-1213), mean corrected calcium: 
2.55 mmol/l (1.95-3.33) and median PTH 167 pmol/l (2.4 - >201). Thirty-five lesions were detected 
on planar and SPECT and this was unchanged after assessment of the LDCT data. Confidence for the 
presence of parathyroid pathology changed in 5 patients (5 lesions) with the addition of LDCT. LDCT 
changed the mean confidence of parathyroid pathology from 3.17 to 3.29 (p=0.16). Addition of LDCT 
reduced the number of equivocal lesions from 18 (14 patients) to 14 (10 patients) (p=0.13). The 
addition of LDCT changed localization in 4 lesions (3 patients). Confidence in localization of 
pathology changed in 9 lesions (7 patients) and the mean localization confidence score was improved 
from 4.2 to 4.46 (p=0.002) with LDCT. The number of lesions classified as ectopic increased from 5 
(on planar+SPECT) to 8 (with addition of LDCT) (p=0.25). 
 
Conclusion: In renal hyperparathyroidism SPECT/LDCT altered localization of lesions detected on 
planar and SPECT alone and improved reader confidence of localization accuracy. SPECT/LDCT 
conferred no additional benefit over SPECT in terms of detection, confidence of parathyroid 
pathology or ability to distinguish equivocal from non-equivocal parathyroid lesions. The addition of 
LDCT did not detect significantly more ectopic lesions. Whereas the minor improvement in reader 
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confidence of localization (with addition of LDCT) was of questionable clinical significance, we 
speculate that the changed and presumably improved localization of lesions on SPECT/LDCT had 
potential clinical impact in a significant proportion of patients. On this basis we recommend the use of 
hybrid SPECT/LDCT in imaging of renal hyperparathyroidism when surgery is considered. 
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ABSTRAK 
 
Agtergrond: Hibriedbeelding met enkelfoton emissie rekenaartomografie / lae dosis 
rekenaartomografie (EFERT/LDRT) is voordelig in pre-operatiewe beelding van primêre 
hiperparatiroïedisme. Die rol van EFERT/RT in pre-operatiewe evaluering van renale 
hiperparatiroïedisme is nog nie ondersoek nie. Die doel van hierdie studie was om in hierdie 
pasiëntgroep te bepaal of EFERT/RT 'n voordeel bo EFERT alleen verleen.  
 
Metode: 'n Retrospektiewe studie van pasiënte met renale hiperparatiroïedisme en positiewe planare 
en EFERT flikkergrafie is onderneem. Na die toediening van 
99m
Tc-pertegnetaat is planare beelding 
op alle pasiënte gedoen, onmiddellik gevolg deur 
99m
Tc-sestamibi sowel as EFERT/RT beelding 60 
min na sestamibi inspuiting en 'n laat statiese beeld vir differensiële uitwas op 2-3 uur. Planare 
subtraksiebeelde is verkry. Twee kerngeneeskundiges het die planare + EFERT beelde van elke 
pasiënt gerapporteer, waarna die planare + EFERT/RT beelde met die hulp van 'n radioloog 
gerapporteer is. Sekerheid oor die teenwoordigheid van hiperfunksionerende paratiroïedweefsel 
sowel as die sekerheid oor die lokalisering daarvan, is op 'n Likert-tipe skaal verkry. Interpretasie 
van planare + EFERT is vergelyk met die interpretasie van planare + EFERT/RT. Die impak van 
LDRT op twyfelagtige letsels en die aantal ektopiese letsels waargeneem, is ook bepaal. 
 
Resultate: Twintig pasiënte (M:13; F:7) met beelding tussen Februarie 2008 en Junie 2011 is 
ingesluit [gemiddelde ouderdom: 40 jaar (24-55)] . Die gemiddelde kreatinien was 687 μmol/l (169-
1213), gemiddelde gekorrigeerde kalsium 2.55 mmol/l (1.95-3.33) en mediaan PTH 167 pmol/l (2.4-
>201). Vyf en dertig letsels is op planare en EFERT beelde waargeneem en was onveranderd na 
assessering van die LDRT-data. Sekerheid oor die teenwoordigheid van paratiroïedpatologie het 
verander in 5 pasiënte (5 letsels) met die toevoeging van LDRT. LDRT het die gemiddelde sekerheid 
van paratiroïedpatologie van 3.17 tot 3.29 verander (p = 0.16). Toevoeging van LDRT het die aantal 
twyfelagtige letsels van 18 (14 pasiënte) tot 14 (10 pasiënte) verminder (p = 0.13). Die byvoeging van 
LDRT het die lokalisering in 4 letsels (3 pasiënte) verander. Sekerheid oor die lokalisering van 
patologie is in 9 letsels (7 pasiënte) verander en die gemiddelde lokalisering betroubaarheidswaarde 
is verbeter van 4.2 tot 4.46 (p = 0.002) met LDRT. Met die byvoeging van LDRT het die aantal letsels 
geklassifiseer as ektopies van 5 tot 8  (p = 0.25) toegeneem. 
 
Gevolgtrekking: In renale hiperparatiroïedisme het EFERT/RT die lokalisering van letsels wat op 
planare + EFERT beelding alleen waargeneem is, verander en die leser se vertroue om akkuraat te 
lokaliseer verbeter. EFERT/LDRT het geen bykomende voordeel bo EFERT in terme van die 
opsporing, sekerheid van paratiroïedpatologie of onderskeidingsvermoë tussen twyfelagtige teenoor 
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nie-twyfelagtige paratiroïedletsels verleen nie. Met die byvoeging van LDRT is nie beduidend meer 
ektopiese letsels gevind nie. Terwyl die geringe verbetering in die sekerheid van lokalisering (met die 
byvoeging van LDRT) van twyfelagtige kliniese betekenis was, spekuleer ons dat die verandering en 
vermoedelik verbeterde lokalisering van letsels op EFERT/LDRT ŉ potensiële kliniese impak het in 'n 
beduidende aantal pasiënte. Die gebruik van EFERT/LDRT in die beelding van renale 
hiperparatiroïedisme wanneer chirurgie oorweeg word, word dus vir bogenoemde rede aanbeveel. 
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INTRODUCTION AND LITERATURE REVIEW 
 
In contrast to de novo neoplasia or hyperplasia of one or more of the parathyroid glands in primary 
hyperparathyroidism, secondary hyperparathyroidism refers to parathyroid hyperplasia in reaction to a 
chronic hypocalcaemic condition (most commonly renal failure), while tertiary hyperparathyroidism 
occurs almost exclusively in the context of long-standing renal disease when hyperplastic parathyroid 
glands develop functional autonomy and are no longer suppressible by correction of hypocalcaemia. 
While the diagnosis of hyperparathyroidism is principally biochemical, parathyroid scintigraphy has 
an established role in the detection of hyperfunctioning parathyroid tissue when surgery is being 
considered.
1
 
 
While preoperative scintigraphy may be routinely indicated in cases of primary hyperparathyroidism, 
in renal hyperparathyroidism preoperative scintigraphy is also performed. Scintigraphy’s main role in 
the renal patient group has been for detection of residual or recurrent hyperfunctioning glands post-
surgery.
1–9
 Routine preoperative scintigraphy of secondary or tertiary hyperparathyroidism is also 
performed by some centres. This is done based on its potential to reduce operative time, perform less 
extensive dissection, and to detect supernumerary or ectopic glands and thereby reduce the rate of 
surgical failure.
5,10–14
 In addition it is possible that scintigraphy may be useful to plan management 
(surgical or medical), and to identify parathyroid tissue that should be conserved. 
15
 Its role is however 
controversial, in part due to the widely varying sensitivity (34-94%) and poor localization reported by 
several studies.
5,6,10,11,16–29
 It can also be argued that surgical intervention in these cases typically 
mandates bilateral exploration and that accurate localization is therefore not as important as in cases 
of primary hyperparathyroidism in which minimally-invasive surgery is sometimes performed.
5,30
 
 
The role of single photon emission computed tomography (SPECT) and hybrid imaging using SPECT 
together with a low-dose x-ray computed tomography (SPECT/LDCT) has been well-established for 
primary hyperparathyroidism. SPECT improves sensitivity and localization
29,31–37
 and while 
SPECT/LDCT has no incremental value in sensitivity over SPECT alone,
8,31
 it has been shown to 
improve localization.
8,31,38–40
 While SPECT has been shown to increase sensitivity in detecting lesions 
in secondary and tertiary hyperparathyroidism,
18,26,29,41
 and the value of SPECT fused with diagnostic 
CT in renal hyperparathyroidism has been demonstrated,
42
 the role of SPECT/LDCT in this specific 
group has not been examined.  
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AIM OF THE INVESTIGATION 
 
Our goal in this study was to determine the incremental value, if any, of performing SPECT/LDCT 
compared to SPECT, in cases of renal hyperparathyroidism. 
 
MATERIALS AND METHODS 
 
Patient selection 
 
The scintigraphic studies of all patients with renal hyperparathyroidism (confirmed by laboratory and 
clinical data) who were referred to our department between February 2008 and June 2011 for 
parathyroid scintigraphy were reviewed. SPECT/CT was performed in all cases. Three patients had 
repeat scans and in these cases, the study with the most recent correlating biochemical data was 
selected. Only patient scans with lesions visible on SPECT were included in our study group. The 
study was conducted in accordance with established ethical guidelines and was approved by the ethics 
committee of our institution (Ref # N11/06/197). 
 
Measures of Renal Disease 
 
Information regarding specific renal pathology, medical management of hyperparathyroidism, 
dialysis, and whether a renal transplant had been performed was obtained for all patients. These data 
were recorded using a standardized data sheet. 
 
Biochemical and Pathological Markers 
 
Most recent plasma levels of parathyroid hormone, urea, creatinine, corrected calcium and phosphate 
at time of the scan were obtained. Parathyroid hormone levels post-surgery (if performed) were also 
recorded. The pathology and location of resected glands and masses were obtained when available. 
 
Image Acquisition 
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Both subtraction and dual-phase techniques were used in imaging. All patients underwent planar 
scintigraphy using 
99m
Tc-pertechnetate (imaging 15 min after intravenous injection of 74-111 MBq) 
immediately followed by 
99m
Tc-sestamibi (imaging 5 min after intravenous injection of 740 MBq), as 
well as SPECT/LDCT 60 min after sestamibi injection. Planar subtraction images were generated 
from the acquired sestamibi and pertechnetate planar images. 
Planar images were obtained on an Elscint APEX SPX 4 or Elscint APEX SP 4 camera using a 
pinhole collimator with a hole size of 3mm and a zoom factor of 1.8. A 256 x 256 acquisition matrix 
was used. Two pertechnetate anterior planar images were obtained over the thyroid (with and without 
a marker over sternal notch) at a distance of 5cm from collimator to surface of neck, for 300 seconds 
each. Without allowing the patient to move, sestamibi was then injected via an existing intravenous 
line and 5 minutes later 5 consecutive planar images were obtained in the same way. A single anterior 
image was then obtained at a distance of 20 cm, for 120 seconds. 
Sixty minutes after injection of sestamibi, the patient was moved to an Infinia Hawkeye (GE Medical 
Systems) for SPECT/CT imaging. A Low Energy High Resolution collimator was used with a zoom 
factor of 1. The SPECT was acquired using a 128 x 128 matrix. A step and shoot protocol of 30 
seconds per step, and 3 degrees per step was used and a total of 60 views per camera head was 
performed, giving a total of 120 projections. Both planar and SPECT images were obtained in word 
acquisition mode. 
Immediately after the SPECT, without moving the patient, a low-dose CT was acquired using 10 mm 
slices with a current of 2.5 mA and voltage of 140kV with a 256 x 256 matrix. The CT was acquired 
at 2 revolutions/min for a total imaging time of approximately 11 minutes. 
Transverse SPECT images were reconstructed using an ordered subset expectation maximization 
(OSEM) algorithm with 4 iterations with 30 subsets, and incorporated collimator blurring correction. 
No post-processing filters or attenuation correction was used. 
The CT was reconstructed using a Hann filter with a cut-off frequency of 1. 
A delayed pinhole image (identical imaging parameters to early images) after approximately 2-3 
hours was acquired in most patients to assess differential washout. Planar subtraction images were 
generated. 
 
Image Interpretation 
 
Two Nuclear Medicine Physicians who were blinded to the biochemical, surgical and pathological 
results of the patients, interpreted the scintigraphic studies by consensus by first reporting the planar 
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images together with SPECT, and then the planar images together with SPECT/LDCT. The latter 
study was read together with a radiologist. 
Similar to a method used in a previous study,
38
 the Nuclear Medicine Physicians and Radiologist 
reported on the presence of hyperfunctioning parathyroid tissue, and its location (eutopic: left/right; 
superior/inferior; ectopic: inferior, intrathyroidal, mediastinal) for both planar with SPECT and planar 
with SPECT/LDCT. In addition, readers scored the confidence of hyperfunctioning parathyroid tissue 
(1=negative, 2 = equivocal, 3=moderate, 4=high) and confidence of location of pathology (0 = no 
gland detected, 1=very low, 2=low, 3=equivocal, 4=moderate, 5=high).  
 
Statistical Analysis 
 
In those lesions that were visible on planar and SPECT, comparisons were made between SPECT 
alone and SPECT/LDCT in terms of confidence for the presence of parathyroid pathology and 
confidence of pathology localization. Statistical significance was tested using a least squares means 
analysis of mean confidence scores. Tests of the ability of SPECT/LDCT to reduce the number of 
equivocal lesions and to detect additional ectopic lesions were conducted using a McNemar test. 
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RESULTS 
 
Demographics 
 
Of the 37 scans of patient with secondary or tertiary hyperparathyroidism reviewed, 20 had 
identifiable lesions on SPECT and were included in our retrospective analysis. Thirteen male patients 
and 7 female patients were included with a mean age of 40 years (range: 24 – 55 years). 
 
Pathology and management measures 
 
Measures of renal pathology, biochemistry, management and surgical findings (where available) are 
summarized in Table 1. Since the upper detectable limit of PTH in our institution is 201 pmol/l, and 6 
patients exceeded this level, an accurate mean and maximum for PTH could not be determined (a 
median was determined). 
Of the 20 patients included in the study 5 underwent subsequent parathyroid surgery.  
 
Imaging findings 
 
The impact of LDCT on imaging findings is summarized in Table 2. 
 
Detection 
 
Thirty-five lesions (in 20 patients) were visible on planar and SPECT component of SPECT/LDCT. 
No additional lesions were detected with the addition of LDCT.  
Interpreter confidence for parathyroid pathology changed in 5 lesions (5 patients) with the addition of 
LDCT. Confidence of pathology scores increased in 4 lesions (4 patients) and decreased in 1 lesion (1 
patient). In the latter case, an equivocal focus on SPECT localized to what was interpreted as necrotic 
lymph node on LDCT (Figure 1.) 
The use of hybrid imaging changed the mean confidence from 3.17 (for planar and SPECT) to 3.29 
(for planar and SPECT/LDCT) which was not statistically significant (p=0.16) (Figure 2). The 
addition of LDCT reduced the number of lesions with equivocal scores for pathology (score 2 or 3) 
Stellenbosch University  http://scholar.sun.ac.za
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from 18 (in 14 patients) to 14 (in 10 patients) although this did not reach statistical significance 
(p=0.13) (Figure 3). 
 
Localization 
 
Of the 35 lesions identified on planar images and SPECT, 30 were found to be eutopic (in 19 patients) 
and 5 were found to be ectopic (in 5 patients). Planar and SPECT/LDCT imaging localized 27 lesions 
as eutopic (in 18 patients) and 8 lesions as ectopic (in 7 patients). Although LDCT increased the 
number of ectopic lesions, this was not statistically significant (p=0.25) (Figure 4.) 
With the addition of LDCT the localization of 4/35 lesions changed (in 3 patients): Two glands (in 1 
patient) initially localized as left and right inferior (eutopic) were localized as left and right inferior 
intrathyroidal (ectopic). The location of an additional gland was reclassified from inferior (eutopic) to 
inferior-posterior (ectopic) due to the addition of LDCT (Figure 5). The location of a final focus 
changed from left anterior mediastinal (ectopic) to inferior to left thyroid lobe (ectopic) but the 
discrepancy in interpretation might not have occurred had there not been incorrect positioning of the 
sternal marker on static images. 
Confidence of localization of pathology changed in 9 lesions (7 patients) with the addition of LDCT. 
Mean confidence was improved from 4.2 (for planar and SPECT) to 4.46 (for planar and 
SPECT/LDCT) which was statistically significant (p=0.002) (Figure 6). 
 
Correlation with surgical findings 
 
For those patients who underwent surgery and for whom surgical records were available (n=5), 9 
lesions were detected on scintigraphy while 19 parathyroid glands were resected (identification rate 
47%). Pathological analysis revealed all resected glands to represent parathyroid hyperplasia. 
Unfortunately operative notes did not accurately record their location. The mean mass of resected 
parathyroid glands was 0.91 g.  PTH levels post-surgery were available in 4 patients and demonstrated 
normalization in 2, near-normalization in 1 and persistent elevation in 1.  
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DISCUSSION 
 
In this study we found that the addition of LDCT had no impact on 1.) detection; 2.) confidence of 
parathyroid pathology; 3.) number of equivocal lesions or 4.) number of ectopic lesions detected but  
did have some impact on the localization of hyperplastic and/or autonomous parathyroid tissue in 
renal hyperparathyroidism. 
 
Although sensitivity and specificity could not be quantified in our study (since not all patients 
underwent surgery), no additional lesions were detected on LDCT and therefore there was no impact 
on the sensitivity of the investigation. This is consistent with studies in primary hyperparathyroidism 
that contained small subgroups with secondary hyperparathyroidism, in which sensitivity of SPECT 
and SPECT/LDCT was reported as equal. A study by Serra et al. (2006) comparing SPECT and 
SPECT/LDCT in patients with primary (n=10) and secondary (n=6) hyperparathyroidism found no 
difference in sensitivity between the two modalities.
8
 Similarly, a study by Öksüz et al. (2011) that 
examined patients with primary (n=56) and secondary (n=-4)  hyperparathyroidism reported identical 
sensitivity of SPECT and SPECT/LDCT.
31
  
In our study, the addition of LDCT in the imaging of renal hyperparathyroidism had minimal impact 
on interpretation of lesions already identified. LDCT reduced the confidence of parathyroid pathology 
in 1 lesion out of 35 (in a single patient) from an equivocal parathyroid lesion without LDCT to a 
probable necrotic lymph node with LDCT. If the LDCT interpretation was correct this would have 
resulted in a small improvement in specificity. A minimal impact on specificity by LDCT is 
consistent with the previous study by Lavely et al. (2007) in patients with primary 
hyperparathyroidism (n=110) that reported no significant difference in specificity when comparing 
SPECT and SPECT/LDCT techniques (both > 98%).
38
 Another previous study (using diagnostic CT) 
by Wimmer et al. (2010) reported no significant difference in specificity for CT fused with SPECT 
(93%) compared to SPECT alone (90%) in patients with multiglandular disease (renal 
hyperparathyroidism n= 22; primary hyperparathyroidism n=6).
42
  
In our study, LDCT did not significantly improve interpreter confidence for parathyroid pathology, or 
reduce the number of equivocal lesions. While a previous study by Lavely et al (2007) included 
confidence of pathology scores (including scores for equivocal lesions) when comparing lesions 
detected on SPECT to SPECT/LDCT, no analysis of LDCT impact on confidence of pathology per se 
or number of equivocal lesions was performed.
38
 
 
The localization of 4 out of 35 lesions (in 3 out of 20 patients) in our study was changed by the 
addition of LDCT (in 3 lesions from eutopic to ectopic locations and in 1 lesion from ectopic to 
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another ectopic location). The impact of LDCT may however have been less in the one patient had a 
sternal marker not been incorrectly positioned on planar imaging. The number of lesions in which 
LDCT changed localization is less than that reported in the study by Serra et al. (2006) that compared 
SPECT and SPECT/LDCT in 10 patients with primary hyperparathyroidism and 6 patients with 
secondary hyperparathyroidism. In their study, in the former group LDCT changed the localization of 
7/14 lesions (6 patients) and in the latter group LDCT changed localization in 7/9 lesions (5 patients).
8
  
In our study, LDCT improved interpreter confidence of localization.  While this was statistically 
significant, the increase from a moderate score of 4.2 to a moderate score of 4.46 was of questionable 
clinical significance. A previous study by Lavely et al (2007) which examined LDCT in primary 
hyperparathyroidism measured confidence of localization with LDCT compared to SPECT alone, but 
used the results to assign a binary value (positive/negative for a priori locations) to lesions detected 
and did not examine improvement in localization scores with the addition of LDCT per se.
38
  
Unfortunately accuracy of localization could not be determined in our study since no correlation was 
performed with surgical findings; however it is reasonable to suppose that changes in localization 
with LDCT most likely represented improvements in accuracy by virtue of relation to anatomical 
landmarks. Accuracy of localization has previously been examined using surgical localization as a 
gold standard. There is evidence that SPECT fused with diagnostic CT is more accurate in 
localization of hyperfunctioning parathyroid lesions than SPECT alone in both primary
43,44
 and renal
42
 
hyperparathyroidism.  Improved localization accuracy has also been demonstrated using 
SPECT/LDCT when compared to SPECT alone. Using surgical correlation, the study by Serra et al. 
(2006) in patients with primary (n=10) and secondary (n=6) hyperparathyroidism reported accuracy of 
localization of SPECT in 61% of detected lesions vs. 100% with SPECT/LDCT.
8
 In the study by 
Lavely et al. (2007) in patients with primary hyperparathyroidism (n=110), a confidence of 
localization score of 4 or 5 was interpreted as positive and lower scores as negative. Using location at 
surgery as their gold standard, they evaluated and compared the sensitivity of various combinations of 
early and delayed SPECT with and without LDCT as well as planar imaging. Techniques using 
SPECT/LDCT were quantitatively more accurate in localizing pathological glands than SPECT-only 
techniques.
38
  A study by Pata et al. (2010) reported that SPECT/LDCT correctly localized adenomas 
in patients with primary hyperparathyroidism and nodular goitre (n=33) as determined by operative 
findings in 87.5% of cases compared to 55.6% with SPECT (p=0.0001).
39
 Studies by Ruf et al. (2007) 
in patients with primary hyperparathyroidism
40
 and Öksüz et al. (2011) in patients with primary 
(n=56) and secondary (n=4) hyperparathyroidism
31
 have reported improved accuracy of localization 
with addition of LDCT on a qualitative basis.  
Whether SPECT/LDCT is more accurate in localization of ectopic lesions in renal 
hyperparathyroidism could not be tested in our study since the number of ectopic lesions was too 
small. Future research to examine this might be worthwhile since studies by Ruf et al. (2007) and 
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Öksüz et al. (2011) in primary hyperparathyroidism have demonstrated that LDCT’s increased 
accuracy in localization is most pronounced in ectopic lesions.
31,40
  
In our study, addition of LDCT characterized more lesions as ectopic when compared to planar and 
SPECT imaging alone, although this did not reach statistical significance. This is potentially 
important since the prevalence of ectopic glands in renal hyperparathyroidism may be higher than 
previously recognized.
14
 Lavely et al. (2007), in their study in primary hyperparathyroidism reported 
that SPECT/LDCT detected more inferior-posterior lesions than SPECT alone
38
 although another 
study by Gayed et al. (2005) in primary hyperparathyroidism reported no change in the number of 
ectopic lesions detected.
45
 
It should be noted that changes in localization (with LDCT) were determined with the benefit of a 
radiologist opinion. The impact of LDCT might be less without such assistance in a clinical setting. 
Whether addition of LDCT has a clinical impact is uncertain and was not measured in this study. It 
may however be speculated that the addition of LDCT would have changed management in one 
patient by identifying potential additional pathology (possible necrotic lymph node), and in 3 patients 
by virtue of altered localization. Clinical impact of LDCT in hyperparathyroidism has not been 
extensively studied. Pata et al. (2010) compared two groups of patients with primary 
hyperparathyroidism and nodular goitre, one imaged with SPECT alone (n=18) and one with 
SPECT/LDCT (n=15). The mean operative time in the former group was 56 min and in the latter 
group 38 min (p=0.034).
39
 Other authors have speculated that LDCT may be beneficial due to 
improved direction of the surgeon to ectopic sites, or by avoiding futile exploration for ectopic glands 
which are not present.
38,46
 As mentioned, Lavely et al. (2007) noted that a major advantage of 
SPECT/LDCT was its ability to differentiate between inferior and inferior-posterior glands. They 
speculated that since surgery for inferior-posterior glands is frequently more complex, pre-operative 
knowledge of such lesions would facilitate exploration.
38
 Finally, the reclassification of a gland from 
eutopic to ectopic (more difficult surgery) may influence the decision to perform surgery in a patient 
with high anaesthetic risk. 
 
LIMITATIONS 
 
The retrospective nature of the study meant that data were often incomplete and not standardized. A 
prospective study correlated with anatomical location at surgery as well as objective measures of 
clinical impact of LDCT would be of value. 
In our study, SPECT/LDCT was performed 60 minutes after the sestamibi injection. There is evidence 
to suggest that earlier SPECT (15 – 30 min) has greater sensitivity in primary 
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hyperparathyroidism.
38,47
 Washout of sestamibi prior to tomographic imaging may in part account for 
the reason that only 20 patients of the initial 37 had lesions identifiable on SPECT.  It is possible that 
had our SPECT scans been conducted earlier post-injection, we would have detected more lesions to 
evaluate. 
The major limitation in our study was the absence of a gold standard in the majority of patients. Of 
the 20 patients, only 5 had parathyroid surgery following scintigraphy and surgical notes in these 
cases were limited in detail with respect to localization thus limiting evaluation of accuracy of 
localization of the scintigraphy. While it was not possible to comment on whether the localization 
changes with LDCT represented improvements in localization, this is likely, given the additional 
anatomical information obtained with LDCT.   
Since surgery was not performed in all patients that were scanned (and on none of the patients with 
negative scans), only a detection rate (in this group) could be determined.  
 
CONCLUSION 
 
In our study of patients with renal hyperparathyroidism SPECT/LDCT altered localization of lesions 
detected on planar and SPECT alone and improved reader confidence of localization accuracy. The 
clinical impact of altered localization was not studied. SPECT/LDCT conferred no additional benefit 
over SPECT in terms of detection, confidence of parathyroid pathology or ability to distinguish 
equivocal from non-equivocal parathyroid lesions. The addition of LDCT did not detect significantly 
more ectopic lesions. It is uncertain whether LDCT makes a greater contribution to localization and 
clinical outcome of ectopic lesions in renal hyperparathyroidism (as is suggested by literature in 
primary hyperparathyroidism) and further research is needed to determine this.  
Whereas the minor improvement in reader confidence of localization (with addition of LDCT) was of 
questionable clinical significance, we speculate that the changed and presumably improved 
localization of lesions on SPECT/LDCT had potential clinical impact in a significant proportion of 
patients. On this basis we recommend the use of hybrid SPECT/LDCT in imaging of renal 
hyperparathyroidism when surgery is considered. 
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TABLES 
 
Table 1. Pathological and biochemistry results of study group 
 
Pt Renal diagnosis Creatinine 
(μmol/l)† 
Corrected 
Calcium 
(mmol/l)
 
††
 
PTH 
(pmol/l)
‡
 
Prior 
management 
Parathyroidectomy 
after scan 
Mass of 
excised glands 
(g)
*
 
Repeat PTH 
post-surgery 
(pmol/l)
 ‡
  
1 Mesangiocapillary GN 1210 2.42 >201 CS: Yes 
VDS: Yes 
Dialysis: PD 
Yes LI:1.22 
RI:2.78 
RS:0.16 
>201 
2 Mesangiocapillary GN 541 1.95 >201 CS: Yes 
VDS: ? 
Dialysis: PD 
Yes LI:0.375 
LS:0.335 
RI:0.36 
RS:0.246 
4.5 
3 Chronic GN 611 2.61 27.1 CS: Yes 
VDS: Yes 
Dialysis: HD 
No   
4 ADPKD 302 2.24 148.4 CS: No No   
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VDS: No 
Dialysis: No 
5 Chronic GN 1213 2.24 >201 CS: Yes 
VDS: Yes 
Dialysis: HD 
Yes LI:2.27 
LS:0.1 
RI:0.59 
RS:0.21 
2.7 
6 Malignant Hypertension 691 2.35 178.6 CS: Yes 
VDS: Yes 
Dialysis: PD 
?   
7 Chronic GN 765 2.07 145.1 CS: Yes 
VDS: No 
Dialysis: HD 
No   
8 ? 598 2.63 84.5 CS: ? 
VDS: ? 
Dialysis: ? 
?   
9 Focal segmental GN ? 2.26 153.2 CS: Yes 
VDS: Yes 
Dialysis: HD 
No   
10 Malignant Hypertension 513 3.03 133 CS: Yes No   
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VDS: No 
Dialysis: HD 
11 Chronic GN 993 3.01 170.9 CS: ? 
VDS: Yes 
Dialysis: HD 
No   
12 Malignant Hypertension 670 2.66 414 CS: Yes 
VDS: Yes 
Dialysis: HD 
No   
13 Chronic GN 1200 2.4 105.3 CS: Yes 
VDS: Yes 
Dialysis: HD 
No   
14 Malignant Hypertension 490 2.21 162.8 CS: Yes 
VDS: Yes 
Dialysis: HD 
No   
15 Chronic GN 411 2.93 >201 CS: Yes 
VDS: Yes 
Dialysis: HD 
Yes LI:3.62 
LS:0.16 
RI:0.92 
RS:0.3 
10.1 
16 Reflux nephropathy 169 3.28 >201 CS: No No   
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VDS: No 
Dialysis: HD 
17 Solitary ectopic kidney 
following nephrectomy 
for right dysplastic 
kidney 
749 2.5 172.1 CS: Yes 
VDS: Yes 
Dialysis: HD 
Yes Mass of glands 
unrecorded 
LI,LS,RI: 
parathyroid 
hyperplasia 
LI(2): thyroid 
nodule 
? 
18 Solitary kidney; Reflux 
nephropathy 
791 2.3 48.9 CS: Yes 
VDS: No 
Dialysis: HD 
No   
19 Malignant Hypertension 226 3.33 2.4 CS: No 
VDS: No 
Dialysis: No 
No   
20 Chronic GN 910 2.52 >201 CS: Yes 
VDS: Yes 
Dialysis: HD 
No   
 
 
 
 ̅ 687 2.55 147  
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 (median) 
Range 169 – 1213 1.95 – 
3.33 
2.4 - 
>201 
 
PTH: Parathyroid Hormone, GN: glomerulonephropathy, ADPKD: Autosomal Dominant Polycystic Kidney Disease, CS: Calcium supplementation, VDS: 
Vitamin D supplementation, HD: Haemodialysis, PD: Peritoneal Dialysis, LI: Left inferior, LS: Left superior, RI: Right inferior, RS: Right superior, ? 
Unknown 
† 
Reference range: 60 – 120 μmol/l, †† Reference range: 2.05 – 2.56 mmol/l, ‡ Reference range: 1.2 – 8.5 pmol/l, * Normal: < 0.04 g 
 
Table 2. Impact of LDCT on study interpretation: 
 
Patient Gland Planar + SPECT Planar + SPECT/LDCT 
Pathology 
confidence score 
 
Location Location 
confidence score 
Pathology 
confidence score 
Location Location 
confidence score 
1 1 4 LI 4 ~ ~ 5 
 2 2 E: midline inf 4 4 ~ 5 
2 1 2 LS 4 ~ ~ ~ 
3 1 2 LI 4 ~ ~ ~ 
4 1 2 RI 4 ~ ~ ~ 
 2 4 E: LAM 4 ~ E:inf to L 5 
5 1 4 LI 4 ~ ~ ~ 
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6 1 3 LS 4 ~ ~ ~ 
 2 4 LI 4 ~ ~ ~ 
 3 4 RS 4 ~ ~ 5 
7 1 2 LI 4 ~ ~ ~ 
 2 2 RI 4 3 ~ 5 
8 1 4 RI 5 ~ ~ ~ 
9 1 2 LS 4 ~ ~ ~ 
 2 3 LI 4 ~ ~ ~ 
10 1 4 LS 5 ~ ~ ~ 
 2 4 LI 4 ~ ~ ~ 
11 1 4 E: LIP 5 ~ ~ ~ 
 2 3 RI 5 4 ~ ~ 
12 2 4 RS 4 ~ ~ ~ 
13 2 3 LI 4 ~ ~ ~ 
14 1 4 LI 5 ~ ~ ~ 
 2 4 RI 5 ~ ~ ~ 
15 1 4 LI 4 ~ E: LIIT 5 
 2 4 RI 4 ~ E: RIIT 5 
16 1 4 LI 5 ~ E: LIP ~ 
 2 3 RI 4 ~ ~ ~ 
17 1 4 LS 4 ~ ~ ~ 
 2 3 RI 4 4 ~ 5 
 3 4 E: inf to L 4 ~ ~ ~ 
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18 1 2 LS 4 ~ ~ ~ 
 2 2 LI 4 ~ ~ ~ 
19 1 2 E: thoracic inlet R 4     1  ʄʄ ~ 5 
20 2 3 LI 4 ~ ~ ~ 
 3 2 RS 4 ~ ~ ~ 
 
Mean 3.17  4.2 3.28  4.46 
 
LI: Left inferior, RI: Right inferior, LS: Left superior, RS: Right superior, E: Ectopic, LIP: Left inferior-posterior, LIIT: Left inferior intrathyroidal, RIIT: 
Right inferior intrathyroidal, inf to L: inferior to left thyroid lobe, inf to R: inferior to right thyroid lobe, midline inf: inferior to thyroid in the midline, LAM: 
left anterior mediastinum, thoracic inlet R: thoracic inlet right 
~ Unchanged  
ʄʄ LDCT demonstrated lesion most likely necrotic node and not parathyroid 
 
  
Stellenbosch University  http://scholar.sun.ac.za
Stellenbosch University  http://scholar.sun.ac.za
23 
 
ILLUSTRATIONS 
 
 
 
Figure 1. Planar and tomographic images of patient 35 demonstrating equivocal focus on planar imaging. On LDCT, this lesion was interpreted as most likely 
representing necrotic lymph node by the radiologist. 
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Figure 2. Impact of LDCT on pathology confidence score 
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Figure 3. Impact of LDCT on proportion of equivocal lesions 
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Figure 4. Impact of LDCT on proportion of ectopic lesions 
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Figure 5. Planar and tomographic images of patient 29. Localization of the left focus was initially recorded as left inferior (eutopic) on interpretation of 
planar and SPECT data. Addition of LDCT altered localization to left inferior-posterior. 
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Figure 6. Impact of SPECT/LDCT on localization confidence score 
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